China's fast-growing armed forces face increased scrutiny over how they are spending what is now the world's second-largest military budget.
In a city notorious for its murder rate, more than 90 percent of victims are black. To help break the cycle, police are testing a new approach: trying to win the hearts and minds of middle-schoolers.
Pfizer, the giant drugmaker, is the latest American company seeking a foreign merger to elude U.S. taxes. Public advocacy groups call such deals unfair and want Congress to crack down.
The ACA may eventually smooth out the volatility in health insurance costs for small businesses. But for the next few years, it could be a bumpy — and expensive — ride for some firms.
The U.N. envoy for Syria, Lakhdar Brahimi, quit in frustration over the difficulties of bringing an end to the civil war and the failure of the United Nations to intervene.
Senate Majority Leader Harry Reid had made a vote on the Keystone XL pipeline contingent upon passage of the energy efficiency bill. Most Democrats don't want a vote on Keystone.
After 41 years in Washington, Sen. Thad Cochran holds clout in Washington — and his name is on buildings across the state. But a Tea Party candidate says the time for that kind of largesse is over.
About a quarter of the 200,000 Holocaust survivors in Israel live below the poverty line. The government is now pushing a plan to increase assistance.
Perhaps you're well aware of the BRIC countries. But now there's MINT and CIVET and more. Emerging markets have fared poorly the past few years, but they are still cranking out lots of acronyms.
France's $1.6 billion sale is the biggest ever by a NATO country to Russia. But in the wake of Russia's actions in Ukraine, the French are debating whether they should suspend the deal.